- Adhera Therapeutics (OTCPK:ATRX) announces that a new European patent has been issued for MLR-1019 (armesocarb), a drug licensed by the company from Melior Discovery.
- With the latest addition, MLR-1019 has been issued 11 patents (3 in U.S., Europe Union, Australia, Chinese, Eurasia, Israel, Mexico, South Africa, and Hong Kong).
- Adhera intends to initiate a Phase 2a trial in an Eastern European jurisdiction where mesocarb still has marketing registration.
- The company will undertake a parallel process in the U.S. with Investigational New Drug (IND)-enabling studies.
Adhera gets European patent covering MLR-1019
Recommended For You
About ATRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ATRX | - | - |
Adhera Therapeutics, Inc. |